{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:56:59Z","timestamp":1791100619891,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.clinthera.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T07:45:18Z","timestamp":1237448718000},"page":"370-385","source":"Crossref","is-referenced-by-count":47,"title":["Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 \u03bcg and fluticasone propionate 250 \u03bcg: Implications for establishing bioequivalence of inhaled products"],"prefix":"10.1016","volume":"31","author":[{"given":"Peter T.","family":"Daley-Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector G.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.02.007_bib1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1742-1241.2007.01382.x","article-title":"The Diskus: A review of its position among dry powder inhaler devices","volume":"61","author":"Chrystyn","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2009.02.007_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.04.044","article-title":"Dry powder inhalers (DPIs)\u2014a review of device reliability and innovation","volume":"360","author":"Islam","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2009.02.007_bib3","first-page":"133","article-title":"Therapeutic equivalence of inhaled corticosteroids\u2014Workshop on regional differences in regulatory requirements","volume":"1","author":"Fuglsang","year":"2008","journal-title":"Respiratory Drug Delivery"},{"key":"10.1016\/j.clinthera.2009.02.007_bib4","first-page":"151","article-title":"Can we move toward harmonized requirements for bioequivalence of inhalers?","volume":"1","author":"Byron","year":"2007","journal-title":"Respiratory Drug Delivery Europe"},{"key":"10.1016\/j.clinthera.2009.02.007_bib5","first-page":"145","article-title":"In vitro bioequivalence of particle size distributions: A commentary on FDA's draft guidance","volume":"1","author":"Byron","year":"2002","journal-title":"Respiratory Drug Delivery VIII"},{"key":"10.1016\/j.clinthera.2009.02.007_bib6","first-page":"125","article-title":"Quality by design (QbD): What type of in vivo- in vitro correlations are feasible?","volume":"1","author":"Byron","year":"2008","journal-title":"Respiratory Drug Delivery"},{"key":"10.1016\/j.clinthera.2009.02.007_bib7","first-page":"101","article-title":"Proving inhaled corticosteroid equivalence: What are the clinically acceptable differences in performance?","volume":"1","author":"Ahrens","year":"2008","journal-title":"Respiratory Drug Delivery"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.02.007_bib8","first-page":"2.9.18","article-title":"Preparations for inhalation","year":"2001","journal-title":"European Pharmacopoeia"},{"key":"10.1016\/j.clinthera.2009.02.007_bib9","series-title":"Guidance for Industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. Chemistry, manufacturing, and controls documentation","year":"1998"},{"key":"10.1016\/j.clinthera.2009.02.007_bib10","series-title":"Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Doc Ref. CPMP\/ EWP\/4151\/00 Rev 1","year":"2007"},{"key":"10.1016\/j.clinthera.2009.02.007_bib11_1","unstructured":"Drugs and Health Products. Release of Draft Guidance Document: Submission Requirements for Subsequent Market Entry Inhaled Corticosteroid Products for Use in the Treatment of Asthma"},{"key":"10.1016\/j.clinthera.2009.02.007_bib12_1","unstructured":"US Food and Drug Administration (FDA) Federal Register: June 5, 2008 (Volume 73, Number 109), Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting [FDA Web site]"},{"key":"10.1016\/j.clinthera.2009.02.007_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jamp.2007.0643","article-title":"In vitro\/in vivo comparisons in pulmonary drug delivery","volume":"21","author":"Newman","year":"2008","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.clinthera.2009.02.007_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaerosci.2003.12.006","article-title":"Particle deposition measurements and numerical simulation in a highly idealized mouth-throat","volume":"35","author":"Zhang","year":"2004","journal-title":"J Aerosol Science"},{"key":"10.1016\/j.clinthera.2009.02.007_bib15","first-page":"35","article-title":"A comparision of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbohaler inhalers","volume":"6","author":"Malton","year":"1996","journal-title":"J Pharm Med"},{"key":"10.1016\/j.clinthera.2009.02.007_bib16","series-title":"Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics","first-page":"560","article-title":"The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS-MS","author":"Jones","year":"1997"},{"key":"10.1016\/j.clinthera.2009.02.007_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0378-4347(98)00374-0","article-title":"Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry","volume":"718","author":"Callejas","year":"1998","journal-title":"J Chromatog B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2009.02.007_bib18_1","unstructured":"GlaxoSmithKline Clinical Trials Register. The systematic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given alone and in combination, after repeat dosing from Diskus\u2122 inhalers in healthy volunteers"},{"key":"10.1016\/j.clinthera.2009.02.007_bib19_1","unstructured":"US Food and Drug Administration. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations"},{"key":"10.1016\/j.clinthera.2009.02.007_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: The importance of rigorous methods [published correction appears in BMJ. 1996;313:550]","volume":"313","author":"Jones","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.02.007_bib21_1","unstructured":"GlaxoSmithKline Clinical Study Register. A phase I, monocentric, randomised, double-blind, double-dummy, cross-over study to compare the pharmacokinetics and the pharmacodynamic effects of Seretide 50 \u03bcg\/250 \u03bcg bid after repeat dosing,delivered by Diskus\u2122 versus RPID in patients with moderate asthma"},{"key":"10.1016\/j.clinthera.2009.02.007_bib22_1","unstructured":"GlaxoSmithKline Clinical Study Register. A multicentre, randomised, double-blind, double-dummy, parallel-group study to establish equivalence of the salmeterol\/fluticasone propionate combination product (50\/250\u03bcg) via either the reservoir powder inhalation device (RPID) or via the Diskus\u2122 inhaler over 12 weeks in adolescents and adults"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.02.007_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003088-200039001-00002","article-title":"Bioavailability of orally administered micronised fluticasone propionate","volume":"39","author":"Falcoz","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.02.007_bib24","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1089\/jam.1998.11.Suppl_1.S-112","article-title":"Impact of oropharyngeal deposition on inhaled dose","volume":"11","author":"Dolovich","year":"1998","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.clinthera.2009.02.007_bib25","first-page":"389","article-title":"Development and preliminary validation studies with an ex-vivo oropharyngeal model","volume":"1","author":"Newhouse","year":"1998","journal-title":"Respiratory Drug Delivery VI"},{"key":"10.1016\/j.clinthera.2009.02.007_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/027868299304165","article-title":"Particle deposition in a cast of human oral airways","volume":"31","author":"Cheng","year":"1999","journal-title":"Aerosol Sci Technol"},{"key":"10.1016\/j.clinthera.2009.02.007_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/jam.2007.0566","article-title":"Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV\u2013the oropharyngeal retention effect for four inhalation delivery systems","volume":"20","author":"Burnell","year":"2007","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.clinthera.2009.02.007_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/089426801316970295","article-title":"Mouthpiece diameter affects deposition efficiency in cast models of the human oral airways","volume":"14","author":"Lin","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.clinthera.2009.02.007_bib29","first-page":"277","article-title":"DPI powder adhesion properties: The power of centrifugal particle detachment (CPD)","volume":"1","author":"Clarke","year":"2002","journal-title":"Respiratory Drug Delivery VIII"},{"key":"10.1016\/j.clinthera.2009.02.007_bib30","series-title":"Innovations in Dry Powder Inhalation Systems, in Dry Powder Inhalers in The Treatment of Asthma: A Continuing Education Monograph for Physicians, Nurses, Pharmacists, Physician Assistants and Respiratory Therapists","first-page":"10","author":"Kelly","year":"2002"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T19:30:42Z","timestamp":1558207842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0149291809000502"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}